ロード中...
4CPS-160 Use of apremilast in plaque psoriasis as an alternative to biologic treatments
BACKGROUND: Apremilast is a phosphodiesterase4 inhibitor. Two pivotal trials were carried out comparing apremilast to placebo in plaque psoriasis (PP). At week 16, significantly more patients taking apremilast achieved PASI75 (28.8%–33.1%) in both trials, versus placebo (5.3%–5.8%). PURPOSE: To asse...
保存先:
| 出版年: | Eur J Hosp Pharm |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535597/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.251 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|